Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemia
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70135 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Augustin Boudry und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hematology, Biology and Pathology Center, CHU Lille, Lille, France. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GIRCI/Cancéropôle Nord-Ouest, Association Laurette Fugain.
Abstract (Originalsprache)
Measurable residual disease (MRD) is a strong prognostic factor in acute myeloid leukaemia (AML). Next‐generation sequencing (NGS) offers promise but must distinguish true signal from background. We assessed MRD in 98 adult AML patients in first complete remission after intensive chemotherapy using a duplex unique molecular identifier (UMI)‐based NGS capture panel. Error reduction analysis showed up to a 20‐fold decrease in artefactual calls versus conventional sequencing. Linearity studies with serial dilutions confirmed accurate quantification down to 0.01% variant allele frequency. In this cohort, NGS‐MRD positivity did not significantly affect overall survival (OS) or relapse‐free survival (RFS) after one course of chemotherapy. However, NGS‐MRD positivity >0.1%, excluding DNMT3A , TET2 , ASXL1 , IDH1 and IDH2 mutations, was significantly associated with inferior outcomes after two courses (OS: hazard ratio [HR] = 3.04, p = 0.0173; RFS: HR = 2.83, p = 0.0097). Combining multiparameter flow cytometry (MFC‐MRD) with NGS‐MRD identified a double‐positive subgroup with particularly poor outcomes after the first course (OS: HR = 7.98, p < 0.001; RFS: HR = 7.87, p < 0.001). These findings underscore that duplex UMI‐based NGS is a sensitive, quantitative approach for MRD assessment in AML, offering prognostic information complementary to MFC‐MRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Hematology, Biology and Pathology Center, CHU Lille, Lille, France.
- University of Lille, ULR 2694-Metrics, Lille, France.
- Department of Hematology, Claude Huriez Hospital, CHU Lille, Lille, France.
- University of Lille, U1277-Canther, INSERM, Lille, France.
- Department of Hematology and Cell Therapy, CHU Amiens-Picardie, Amiens, France.
- University of Picardie Jules Verne, EA4666-HEMATIM, Amiens, France.
ORCID-Profile: Augustin Boudry, Nicolas Duployez
Förderung
- GIRCI/Cancéropôle Nord-Ouest
- Association Laurette Fugain
Zitieren
APA
Boudry, A., Goursaud, L., Lebon, D., Dumezy, F., Harrivel, V., Boue-Raguet, A., Joudinaud, R., Marceau-Renaut, A., Geffroy, S., Hauspie, C., Brijs, J., Fenwarth, L., Berthon, C., Marolleau, J. P., Figeac, M., Preudhomme, C., & Duployez, N. (2025). Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70135
Vancouver
Boudry A, Goursaud L, Lebon D, Dumezy F, Harrivel V, Boue-Raguet A, et al. Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemia. British Journal of Haematology. 2025. doi:10.1111/bjh.70135
BibTeX
@article{Boudry2025,
author = {Boudry, Augustin and Goursaud, Laure and Lebon, Delphine and Dumezy, Florent and Harrivel, Véronique and Boue-Raguet, Alexandre and Joudinaud, Romane and Marceau-Renaut, Alice and Geffroy, Sandrine and Hauspie, Carine and Brijs, Jan and Fenwarth, Laurène and Berthon, Céline and Marolleau, Jean-Pierre and Figeac, Martin and Preudhomme, Claude and Duployez, Nicolas},
title = {Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemia},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70135}
}
EUVIMED